Trending

view more
Taking action to address Europe’s non-communicable disease epidemic

Taking action to address Europe’s non-communicable disease epidemic

Stefan Woxström at AstraZeneca considers the high rates of non-communicable diseases and how governments and healthcare systems can improve their treatments

 1 October 2023
Women’s health in the UK: an in-depth overview

Women’s health in the UK: an in-depth overview

Tina Backhouse from Theramex considers the issues with the current standard of women’s healthcare in the UK, and what steps need to be taken to improve this

 1 October 2023
Gender diversity: a critical component in clinical trials

Gender diversity: a critical component in clinical trials

Alicia Staley from Medidata explores the need for diversity in clinical trials, especially in terms of gender diversity, and how this can improve outcomes of clinical trials

 1 October 2023
The AI frontier: transforming immunotherapy with intelligent drug discovery

The AI frontier: transforming immunotherapy with intelligent drug discovery

Vicky Qu at BioMap considers the use of artificial intelligence in immuno-oncology and how its use can improve conventional drug discover y processes

 1 October 2023
Repairing not destroying: the future of targeted cancer drug design

Repairing not destroying: the future of targeted cancer drug design

Lukasz Jaremko from King Abdullah University of Science and Technology, Saudi Arabia explains how using nuclear magnetic resonance to study the dynamics of epigenetic targets may enable drug development that does not kill but resets cancer cells to a benign state

 1 October 2023
To achieve diversity in clinical trials, patient-led drug development is key

To achieve diversity in clinical trials, patient-led drug development is key

Amy McKee from Parexel considers the need for diversity in oncology clinical trials in order to fully realise the potential of personalised medicine

 1 October 2023

Rare Diseases

Rare Diseases
Rising to the unique challenges of rare diseases

Rising to the unique challenges of rare diseases

Aaron Bean at Veeva explores the challenges of rare diseases: With up to 30 million people in EU living with rare diseases, Veeva discusses the challenges facing these rare diseases

Rare Diseases, 1 December 2022
The changing landscape of rare disease research

The changing landscape of rare disease research

Pharmafile speaks to Chiesi Group: Chiesi Group tells Pharmafile about the challenges facing rare disease research and their hopes for the future of this area

Rare Diseases, 1 December 2022
The power of partnership: Collaborating with PAOs for better clinical research

The power of partnership: Collaborating with PAOs for better clinical research

Patient advocacy organisations can form an effective partnership between clinical trials and patients for more efficient trials

Rare Diseases, 1 December 2022
Helping rare diseases emerge from the shadows to take centre stage

Helping rare diseases emerge from the shadows to take centre stage

The rare disease treatment market has been rapidly changing and receive deserved recognition

Rare Diseases, 1 December 2022
The combination treatment challenge

The combination treatment challenge

Takeda tells Pharmafile about the role of combination treatments in rare diseases, and strategies to make them more accessible

Rare Diseases, 31 May 2022
Rare diseases and exceptional solutions

Rare diseases and exceptional solutions

Many advancements have been made within the rare disease field, including gene editing and viral delivery strategies

Rare Diseases, 31 May 2022

Infectious Diseases

Infectious Diseases
The AI frontier: transforming immunotherapy with intelligent drug discovery

The AI frontier: transforming immunotherapy with intelligent drug discovery

Vicky Qu at BioMap considers the use of artificial intelligence in immuno-oncology and how its use can improve conventional drug discover y processes

Oncology, 1 October 2023
Repairing not destroying: the future of targeted cancer drug design

Repairing not destroying: the future of targeted cancer drug design

Lukasz Jaremko from King Abdullah University of Science and Technology, Saudi Arabia explains how using nuclear magnetic resonance to study the dynamics of epigenetic targets may enable drug development that does not kill but resets cancer cells to a benign state

Oncology, 1 October 2023
To achieve diversity in clinical trials, patient-led drug development is key

To achieve diversity in clinical trials, patient-led drug development is key

Amy McKee from Parexel considers the need for diversity in oncology clinical trials in order to fully realise the potential of personalised medicine

Oncology, 1 October 2023
The changing treatment landscape for follicular lymphoma

The changing treatment landscape for follicular lymphoma

Dr Mitchell Smith and Dr Julie Dodds tell Pharmafile about recent R&D in the field of blood cancers including follicular lymphoma

Oncology, 1 October 2023
Prostate cancer: new screening measures and decreasing mortality rates

Prostate cancer: new screening measures and decreasing mortality rates

Professor Hendrik van Poppel talks to Pharmafile about new campaigns to improve prostate cancer screening, the current standard-of-care treatments and what obstacles still need to be addressed in treatment

Oncology, 1 October 2023

Dermatology

view more
Scratching the surface of eczema care in the UK

Scratching the surface of eczema care in the UK

Pharmafilespeaks to Allergy UK: Allergy UK explores the future of eczema diagnosis, treatment, and support

Dermatology, 1 December 2021
Dermatologically speaking: Finding new treatments for women

Dermatologically speaking: Finding new treatments for women

Organon discusses the ways in which women's skin conditions can be managed

Dermatology, 1 December 2021
Insight and oversight: Making the most of virtual platforms in dermatology

Insight and oversight: Making the most of virtual platforms in dermatology

FIDE discuss the need for communication between patients and their HCPs, specifically with virtual platforms in mind, and how this can improve dermatology care

Dermatology, 1 December 2021
“The pain keeps me awake at night. I can’t cope with this anymore”

“The pain keeps me awake at night. I can’t cope with this anymore”

There have been significant advances in dermatological care, this article explores this as well as looking forward to what still needs to be done

Dermatology, 1 December 2021
Supporting dermatology and oncology services to build back better post-COVID-19

Supporting dermatology and oncology services to build back better post-COVID-19

The COVID-19 pandemic has been challenging service-wide for the NHS, but the pharma industry can support patients and the NHS going forward

Dermatology, 1 December 2021
Medical cannabis - The inhaled answer to cancer and non-cancer pain?

Medical cannabis - The inhaled answer to cancer and non-cancer pain?

Pharmafile speaks to Sapphire Clinics: Sapphire Clinics discuss the benefits of medical cannabis for pain management and how this has changed in the last decade

 31 May 2022
Embracing transdermal technologies

Embracing transdermal technologies

Pharmafile speaks to Futura for their insights into the effective delivery of drugs for pain management and alternative technologies

 31 May 2022
Pain management and pharmaceutical compounding

Pain management and pharmaceutical compounding

Pain management is key for both patient and HCP, but how can compounding medication aid in treatment?

 31 May 2022
Samedan